Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT162b2 Variant-Adapted Vaccine in Children and Adults
NCT07798648Phase 3Recruiting
- Sponsor
- BioNTech SE
- Start
- Aug 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tozinameran in coronavirus disease 2019 (COVID-19) (9 cohorts), sponsored by BioNTech SE. Primary endpoints: Percentage of participants reporting local reactions or systemic events at 7 days, Percentage of participants reporting adverse events at 1 month and 2 more. Started Aug 2026; status: recruiting.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07798648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07798648.